CMC Biologics and OncoSynergy agreed on Tuesday to collaborate on the development and manufacturing of OS2966 as a potential Ebola treatment.
An experimental monoclonal antibody treatment, OS2966 was designed to inhibit a cellular adhesion receptor called CD29, which is responsible for the spread of aggressive cancer tumors. The U.S. Food and Drug Administration approved the drug for testing on human subjects who have glioblastoma, a type of brain cancer, earlier this year.
Research has since shown that OS2966 also may stop Ebola from spreading throughout a patient's body.
"Our experience with CMC Biologics' cell line and process development capabilities to develop ... material for our clinical studies in cancer has been outstanding," Dr. Shawn Carbonell, founder and CEO of OncoSynergy, said. "They have exceeded expected expression levels in a high productivity system while producing quality material. Excellent technical capabilities applied to cell line development; rapid sophisticated product analysis; and streamlined formulation development have resulted in an expedited path to provide material for Ebola clinical trials."
The World Health Organization recently reported that 18,000 people have been infected with the Ebola virus in the current outbreak in West Africa. The virus’ mortality rate exceeds 60 percent.
"We are truly honored to be a strategic partner with OncoSynergy to help address this current global health crisis and deploying resources necessary to produce clinical material as quickly as possible" Gustavo Mahler, global chief operations officer of CMC Biologics, said. "Given our strong relationship, we were able to quickly put in place an agreement that enables aggressive timelines and provides a progressive cost-structure that benefits this global health program."